An interventional study of treatment with the Azurion system with Xres5 and Azurion with Clairy IQ in Coronary Artery Disease, sponsored by Philips Clinical & Medical Affairs Global. Active, not recruiting at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Coronary Artery Disease by Philips — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Philips.
Among the 13 studies in Coronary Artery Disease by Philips, this one is the only one that started in 2025, is one of 6 with no phase, and was the 13th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 13 studies in Coronary Artery Disease by Philips is open now, in 12 countries. Recruiting first, the newest first:
Philips Clinical & Medical Affairs Global · Sites in United States, Australia, Austria and 15 more countries
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 824 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 232 across the 6 interventional studies, 291 across the 7 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Philips Clinical & Medical Affairs Global, one of the names counted as Philips. Under that name alone:
Philips Clinical & Medical Affairs Global is the lead sponsor of 86 studies on the registry; 25 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 13 (81%) have results posted.
1 of the studies in Coronary Artery Disease by Philips that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06944509Philips Clinical & Medical Affairs GlobalRADIQAL Study (Radiation Dose and Image Quality Trial) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Coronary Artery Disease by Philips, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Azurion R4.0 is developed by Philips Medical Systems Nederland B.V., a Philips Healthcare company. The Azurion is an interventional X-ray system which is used for live X-ray imaging during invasive cardiac procedures. The proposed Azurion R4.0 includes new x-ray image postprocessing (Xres5) compared to its predecessor, which was equipped with ClarityIQ image post-processing (Xres4).
Azurion R4.0 is a cleared device for EU-MDR regulated countries, submission for FDA510K clearance in the US is pending. Sites in the US will only be activated in the study after FDA clearance.
This is a prospective, randomized, unblinded, comparative, international, multi-center clinical investigation. Randomization will be 1:1 between Xres5 and ClarityIQ (Xres4). Stratification will be performed per site on intended procedure type (based on clinical presentation) and patient BMI.
Primary objective is to demonstrate that in coronary procedures, Xres5 can reduce overall patient radiation dose compared to the current ClarityIQ without affecting procedural performance.
It is expected that 824 subjects are necessary to collect sufficient data for the evaluation of the objectives of this clinical study. The enrollment period is expected to last for 12 months. The study will be executed in Spain, Czech republic, Denmark and the US.
The study procedures consist of three main steps: 1) patient screening and written informed consent, 2) baseline assessment and randomization and 3) treatment with the Azurion system with Xres5 [intervention] or the standard of care (ClarityIQ/Xres4) [control]. Patients will be randomly assigned to either the intervention group or the control group (using the standard of care) in a 1:1 ratio. The coronary procedure will be conducted as per institutional standards and at the discretion of the operator, but the standard image processing will be based on the randomization result. If randomized to the intervention group (Xres5), it will always be possible for the operator to cross over to the standard of care imaging processing (Clarity IQ). For the study sites in EU the primary staff in the intervention room will be wearing electronic staff dosimeters which will log the radiation exposure per staff member per procedure.
After the procedure, characteristics of the patient and procedure are captured in an eCRF. The imaging runs will be uploaded in the cloud after de-identification. After the study the radiation dose (DAP and Air Kerma) will be read out from the system.
The study procedures will end after the coronary procedure is completed. There will be no modifications in the standard of care patient treatment or follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
treatment with the Azurion system with Xres5
Device: treatment with the Azurion system with Xres5
the standard of care (ClarityIQ/Xres4)
Other: Azurion with Clairy IQ
treatment with the Azurion system with Xres5
Azurion system with the standard of care (ClarityIQ/Xres4)
Patient radiation dose and procedural performance (ClarityIQ vs Xres5)
\- Cumulative Dose Area Product (DAP) \[Gycm2\] Total patient group - All procedure types
Time frame: during study procedure
Patient radiation dose and procedural performance (ClarityIQ vs Xres5)
\- Cumulative Air Kerma (AK) \[Gy\] Total patient group - All procedure types
Time frame: during study procedure
Patient radiation dose and procedural performance (ClarityIQ vs Xres5)
\- Time System in Use\* \[minutes\] Total patient group - All procedure types
Time frame: during study procedure
Patient radiation dose and procedural performance - High BMI (ClarityIQ vs Xres5)
\- Cumulative DAP \[Gycm2\] High BMI patients (BMI ≥ 30 kg/m2) - All procedures types
Time frame: During study procedure
Patient radiation dose and procedural performance - High BMI (ClarityIQ vs Xres5)
\- Cumulative Air Kerma \[Gy\] High BMI patients (BMI ≥ 30 kg/m2) - All procedures types
Time frame: During study procedure
Patient radiation dose and procedural performance - High BMI (ClarityIQ vs Xres5)
\- Time System in Use\* \[minutes\] High BMI patients (BMI ≥ 30 kg/m2) - All procedures types
Time frame: During study procedure
Patient radiation dose and procedural performance in diagnostic procedures (ClarityIQ vs Xres5)
\- Cumulative DAP \[Gycm2\] Total patient group - ICA procedures
Time frame: During study procedure
Patient radiation dose and procedural performance in diagnostic procedures (ClarityIQ vs Xres5)
\- Cumulative Air Kerma \[Gy\] Total patient group - ICA procedures
Time frame: During study procedure
Patient radiation dose and procedural performance in diagnostic procedures (ClarityIQ vs Xres5)
\- Time System in Use\* \[minutes\] Total patient group - ICA procedures
Time frame: During study procedure
Patient radiation dose and procedural performance in interventional procedures (ClarityIQ vs Xres5)
\- Cumulative DAP \[Gycm2\] Total patient group - PCI and ICA+PCI procedures
Time frame: During study procedure
Patient radiation dose and procedural performance in interventional procedures (ClarityIQ vs Xres5)
\- Cumulative Air Kerma \[Gy\] Total patient group - PCI and ICA+PCI procedures
Time frame: During study procedure
Patient radiation dose and procedural performance in interventional procedures (ClarityIQ vs Xres5)
\- Time System in Use\* \[minutes\] Total patient group - PCI and ICA+PCI procedures
Time frame: During study procedure
Coronary Cine Radiation Dose and procedural performance (ClarityIQ vs Xres5)
\- Cumulative Cine Air Kerma \[Gy\] Total patient group - All procedure types - Coronary Cine Data
Time frame: During study procedure
Coronary Cine Radiation Dose and procedural performance (ClarityIQ vs Xres5)
\- Cumulative Cine DAP \[Gycm2\] Total patient group - All procedure types - Coronary Cine Data
Time frame: During study procedure
Coronary Cine Radiation Dose and procedural performance (ClarityIQ vs Xres5)
\- Time System in Use\* \[minutes\] Total patient group - All procedure types - Coronary Cine Data
Time frame: During study procedure
Coronary Cine Radiation Dose and procedural performance - High BMI (ClarityIQ vs Xres5)
\- Cumulative Cine Air Kerma \[Gy\] High BMI patients (BMI ≥ 30 kg/m2) - All procedure types - Coronary Cine Data
Time frame: During study procedure
Coronary Cine Radiation Dose and procedural performance - High BMI (ClarityIQ vs Xres5)
\- Cumulative Cine DAP \[Gycm2\] High BMI patients (BMI ≥ 30 kg/m2) - All procedure types - Coronary Cine Data
Time frame: During study procedure
Coronary Cine Radiation Dose and procedural performance - High BMI (ClarityIQ vs Xres5)
\- Time System in Use\* \[minutes\] High BMI patients (BMI ≥ 30 kg/m2) - All procedure types - Coronary Cine Data
Time frame: During study procedure
Ultra-low dose cine fluoro rate (Xres5)
\- Air Kerma rate per acquisitions \[mGy/minutes\] Xres5 cases - Total Patient group - All procedure types
Time frame: During study procedure
Staff radiation dose (ClarityIQ vs Xres5)
\- Deep dose Hp(10) \[mSv\] Total Patient group - All procedure types
Time frame: During study procedure
Staff radiation dose (ClarityIQ vs Xres5)
\- Skin dose Hp(0.07) \[mSv\] Total Patient group - All procedure types
Time frame: During study procedure
Iodine contrast volume administered (ClarityIQ vs Xres5)
\- Iodinated contrast volume \[ml\] Total Patient group - All procedure types
Time frame: During study procedure
Patient Radiation Dose - Projection Angles (ClarityIQ vs Xres5)
\- DAP per run \[Gycm2\] Total Patient group - All procedure types
Time frame: During study procedure
Patient Radiation Dose - Projection Angles (ClarityIQ vs Xres5)
\- Air Kerma per run \[Gy\] Total Patient group - All procedure types
Time frame: During study procedure
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 22 months is close to that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Philips Clinical & Medical Affairs Global →